Ponatinib also produces an improvement in progression-free survival compared with imatinib among those with Philadelphia chromosome-positive acute lymphoblastic leukemia in the phase 3 PhALLCON trial.

Conversion from MRD negativity to positivity during maintenance is substantially lower with the quadruplet, and ...

With an FDA approval for its companion diagnostic in bladder cancer, Natera extends its Treatment on MRD strategy, deferring ...

In patients with [newly diagnosed] Ph+ ALL, olverembatinib plus chemotherapy achieved a 63% MRD-negative complete remission ...

In an analysis of the phase III CEPHEUS trial presented at the American Society of Hematology annual meeting, adding daratumumab (Darzalex) to bortezomib (Velcade), lenalidomide (Revlimid), and ...

(RTTNews) - Johnson & Johnson (JNJ) announced data highlighting that DARZALEX FASPRO (daratumumab and hyaluronidase-fihj)-based regimens improve overall and sustained minimal residual disease (MRD) ...

Achieving measurable residual disease (MRD) negativity is a critical endpoint in acute lymphoblastic leukemia (ALL) that strongly correlates with improved long-term survival and reduced relapse risk ...

Iclusig plust reduced-intensity bested Gleevec when it came to MRD-negative complete remission in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Adding Iclusig (ponatinib ...

Please provide your email address to receive an email when new articles are posted on . Those who sustained MRD negativity for more than 6 months achieved longer response duration and PFS. All ...

For patients with early-stage triple-negative breast cancer (TNBC), finishing chemotherapy and surgery should feel like the end of the hardest chapter. But for many, it marks the beginning of a ...